Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025)
Evommune (EVMN) reported Preferred Stock Liabilities of $257.0 million for Q3 2025, up 72.05% year-over-year from $149.4 million in Q3 2024, and up 34.01% quarter-over-quarter from $191.8 million in Q1 2025.
Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Evommune (EVMN) has 2 years of Preferred Stock Liabilities data on file, last reported at $257.0 million in Q3 2025.
- Preferred Stock Liabilities for Q3 2025 came in at $257.0 million, up 72.05% year-over-year; the trailing twelve-month figure through Sep 2025 was $257.0 million (up 72.05% YoY), and the FY2024 annual result was $191.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $257.0 million in Q3 2025 per EVMN's latest filing, from $191.8 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $257.0 million in Q3 2025 and troughed at $149.4 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 257.00 Mn |
| Mar 31, 2025 | 191.78 Mn |
| Dec 31, 2024 | 191.78 Mn |
| Sep 30, 2024 | 149.37 Mn |